tradingkey.logo
tradingkey.logo
Search

Nervgen Pharma Announces Successful End-Of-Phase 2 Meeting And FDA Alignment On Restore, A Phase 3 Registrational Study Of Nvg-291 For Chronic Tetraplegia

ReutersApr 7, 2026 11:45 AM

- NervGen Pharma Corp NGEN.O:

  • NERVGEN PHARMA ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING AND FDA ALIGNMENT ON RESTORE, A PHASE 3 REGISTRATIONAL STUDY OF NVG-291 FOR CHRONIC TETRAPLEGIA

  • NERVGEN PHARMA CORP - RESTORE STUDY INITIATION ON-TRACK FOR MID-2026

  • NERVGEN PHARMA CORP - TO CONCLUDE ENROLLMENT IN PHASE 1B/2A CONNECT SCI SUBACUTE TETRAPLEGIA AND UNBLIND DATA

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI